Publications

5596 Results

Long Term Follow-up from A041202, A Phase 3 Study of Bendamustine/Rituximab vs Ibrutinib or Ibrutinib/Rituximab Shows Continued Efficacy and Safety of Ibrutinib in Older Adults with CLL

Authors
J Woyach;G Burbano;A Ruppert;C Miller;N Heerema;W Zhao;A Wall;W Ding;N Bartlett;D Brander;P Barr;K Rogers;S Parekh;D Stephens;J Brown;G Lozanski;J Blachly;S Nattam;R Larson;H Erba;M Litzow;S Lugar;C Owen;C Kuzma;J Abramson;R Little;S Dinner;R Stone;G Uy;W Stock;S Mandrekar;J Byrd
Journal / Conference
Blood Jan 12:blood.2023021959. doi: 10.1182/blood.2023021959. Online ahead of print
Year
2024
Research Committee(s)
Leukemia
PMID
PMID38215395
PMC
PMC1110309
Study Number(s)
CTSU/A041202

A Phase II Basket Trial of Dual Anti–CTLA-4 and Anti–PD-1 Blockade in Rare Tumors (DART SWOG 1609 Cohort 48) in Patients with Advanced Gallbladder Cancer

Authors
S Patel;E Guadarrama;Y Chae;M Dennis;B Powers;C-Y Liao;W Ferri;T George;E Sharon;C Ryan;M Othus;G Lopez;C Blanke;R Kurzrock
Journal / Conference
Cancer Sep 1;130(17):2918-2927
Year
2024
Research Committee(s)
Early Therapeutics and Rare Cancers
PMID
PMID38358334
PMC
PMC11309904
Study Number(s)
S1609

Diversity of Patients Enrolled in SWOG Gastrointestinal Cancers Therapeutic Trials

Authors
R Safyan;S Colby;C Figueroa-Moseley;K Guthrie;EG Chiorean;PA Philip
Journal / Conference
J Clin Oncol 42, 2024 (suppl 3; abstr 726); ASCO GI Cancers Symposium (January 18-20, 2024, San Francisco, CA, poster
Year
2024
Research Committee(s)
Gastrointestinal

Markers of bone metabolism and overall survival in men with bone-metastatic hormone sensitive prostate cancer (HSPC): a subset analysis of SWOG S1216, a phase III trial of androgen deprivation with or without orteronel [Brief Report]

Authors
P Lara;E Mayerson;E Gertz;C Tangen;A Goldkorn;M Van Loan;M Hussain;S Gupta;J Zhang;M Parikh;P Twardowski;D Quinn;M LeBlanc;I Thompson;N Agarwal
Journal / Conference
Prostate Cancer and Prostatic Diseases Feb 29. doi: 10.1038/s41391-024-00813-3. Online ahead of print
Year
2024
Research Committee(s)
Genitourinary
PMID
PMID38424319
Study Number(s)
S1216

Three- and seven- month prostate-specific antigen levels as prognostic markers for overall survival in metastatic hormone sensitive prostate cancer (mHSPC): Results from SWOG S1216, a phase III randomized trial of androgen deprivation plus orteronel or bicalutamide

Authors
M Parikh;C Tangen;M Hussain;S Gupta;Y Jo;S Callis;A Harzstark;C Paller;S George;M Zibelman;H Cheng;B Maughan;J Zhang;R Pachynski;A Bryce;D Lin;D Quinn;I Thompson;SP Lerner;T Dorff;P Lara;N Agarwal
Journal / Conference
European Urology Oncology Oct;7(5):1097-1104
Year
2024
Research Committee(s)
Genitourinary
PMID
PMID38523017
Study Number(s)
S1216

SWOG S1820: A Pilot Randomized Trial of the Altering Intake, Managing Bowel Symptoms Intervention in Survivors of Rectal Cancer (AIMS-RC)

Authors
V Sun;KA Guthrie;T Crane;K Arnold;S Colby;S Freylersythe;C Braun-Inglis;R Topacio;C Messick;J Carmichael;A Muskovitz;M Nashawaty;M Bajaj;S Cohen;D Flaherty;M O'Rourke;L Jones;R Krouse;C Thomson
Journal / Conference
Cancer Feb 22. doi: 10.1002/cncr.35264. Online ahead of print
Year
2024
Research Committee(s)
Palliative Care
PMID
PMID38386696
PMC
PMC11162313
Study Number(s)
S1820

Analysis of immune-related genes (IRGs) and their potential role in sexual dimorphism in metastatic colorectal cancer (mCRC) patients (pts)

Authors
P Mittal;Y Yang;S Soni;F Battaglin;J Millstein;S Stintzing;A Parikh;J Lo;L Torres-Gonzalez;S Algaze;P Jayachandran;K Ashouri;A Wong;W Zhang;C Mancao;C Cremolini;V Heinemann;I Singh;H-J Lenz
Journal / Conference
ASCO GI Cancers Symposium (January 18-20, 2024, San Francisco, CA), poster; J Clin Oncol 42, 2024 (suppl 3; abstr 182)
Year
2024
Research Committee(s)
Gastrointestinal
Study Number(s)
CTSU/C80405

North American Patterns of Care in Clinical Stage I Testicular Cancer. Secondary Data Use Project for SWOG S1823

Authors
A Morin Coulombe;S Colby;J King;M Neuhouser;B Arun;S Daneshman;A Harzstark;K Arnold;C Nichols;L Nappi
Journal / Conference
ASCO GU Symposium (JAN 25-27, 2024, San Francisco, CA), poster; J Clin Oncol 42, 2024 (suppl 4; abstr 509)
Year
2024
Research Committee(s)
Prevention, Screening, and and Surveillance
Study Number(s)
S1823

Characteristics of Health Care Settings Where Adolescents and Young Adults Receive Care for ALL

Authors
J Wolfson;A Grimes;M Nuno;C Kerber;S Ramakrishnan;M Beauchemin;D Dickens;J Levine;M Roth;M Scialla;W Woods;S Vargas;K Boayue;G Chang;W Stock;D Hershman;E Curran;A Advani;K O'Dwyer;S Luger;J Liu;D Freyer;L Sung;S Parsons
Journal / Conference
JCO Oncology Practice Apr;20(4):491-502
Year
2024
Research Committee(s)
Cancer Care Delivery
PMID
PMID38252911
PMC
PMC11085951

SWOG S2303: Randomized Phase II/III Trial of 2nd Line Nivolumab + Paclitaxel + Ramucirumab versus Paclitaxel + Ramucirumab in Patients with PD-L1 CPS = 1 Advanced Gastric and Esophageal Adenocarcinoma (PARAMUNE)

Authors
A Saeed;S Colby;P Oberstein;D Duda;R Agarwal;C Figeroa-Moseley;R Vaidya;J Unger;K Guthrie;F Rocha;M Senthil;R Safyan;Z Wainberg;S Iqbal;EG Chiorean;PA Philip
Journal / Conference
J Clin Oncol 42, 2024 (suppl 3; abstr TPS430); ASCO GI Cancers Symposium (January 18-20, 2024, San Francisco, CA), TIP, poster
Year
2024
Research Committee(s)
Gastrointestinal